CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study

A. Romigi; M. Bari; C. Liguori; F. Izzi; C. Rapino; M. Nuccetelli; N. Battista; S. Bernardini; D. Centonze; N.B. Mercuri; F. Placidi; M. Maccarrone

doi:10.2174/1871527319666200309115602

CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study

A. Romigi, M. Bari, C. Liguori, F. Izzi, C. Rapino, M. Nuccetelli, N. Battista, S. Bernardini, D. Centonze, N.B. Mercuri, F. Placidi, M. Maccarrone

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	142-147
Number of pages	6
Journal	CNS and Neurological Disorders - Drug Targets
Volume	19
Issue number	2
DOIs	https://doi.org/10.2174/1871527319666200309115602
Publication status	Published - 2020

Access to Document

10.2174/1871527319666200309115602

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086239954&doi=10.2174%2f1871527319666200309115602&partnerID=40&md5=e64c1f73589a5f8468689d74d2a86293

Cite this

Romigi, A., Bari, M., Liguori, C., Izzi, F., Rapino, C., Nuccetelli, M., Battista, N., Bernardini, S., Centonze, D., Mercuri, N. B., Placidi, F., & Maccarrone, M. (2020). CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study. CNS and Neurological Disorders - Drug Targets, 19(2), 142-147. https://doi.org/10.2174/1871527319666200309115602

CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study. / Romigi, A.; Bari, M.; Liguori, C.; Izzi, F.; Rapino, C.; Nuccetelli, M.; Battista, N.; Bernardini, S.; Centonze, D.; Mercuri, N.B.; Placidi, F.; Maccarrone, M.

In: CNS and Neurological Disorders - Drug Targets, Vol. 19, No. 2, 2020, p. 142-147.

Research output: Contribution to journal › Article › peer-review

Romigi, A, Bari, M, Liguori, C, Izzi, F, Rapino, C, Nuccetelli, M, Battista, N, Bernardini, S, Centonze, D , Mercuri, NB, Placidi, F & Maccarrone, M 2020, 'CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study', CNS and Neurological Disorders - Drug Targets, vol. 19, no. 2, pp. 142-147. https://doi.org/10.2174/1871527319666200309115602

Romigi, A. ; Bari, M. ; Liguori, C. ; Izzi, F. ; Rapino, C. ; Nuccetelli, M. ; Battista, N. ; Bernardini, S. ; Centonze, D. ; Mercuri, N.B. ; Placidi, F. ; Maccarrone, M. / CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study. In: CNS and Neurological Disorders - Drug Targets. 2020 ; Vol. 19, No. 2. pp. 142-147.

@article{92f9a37dfb7a47fd9f5302c4fab44d29,

title = "CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study",

author = "A. Romigi and M. Bari and C. Liguori and F. Izzi and C. Rapino and M. Nuccetelli and N. Battista and S. Bernardini and D. Centonze and N.B. Mercuri and F. Placidi and M. Maccarrone",

note = "cited By 0",

year = "2020",

doi = "10.2174/1871527319666200309115602",

language = "Non definita",

volume = "19",

pages = "142--147",

journal = "CNS and Neurological Disorders - Drug Targets",

issn = "1871-5273",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: A pilot study

AU - Romigi, A.

AU - Bari, M.

AU - Liguori, C.

AU - Izzi, F.

AU - Rapino, C.

AU - Nuccetelli, M.

AU - Battista, N.

AU - Bernardini, S.

AU - Centonze, D.

AU - Mercuri, N.B.

AU - Placidi, F.

AU - Maccarrone, M.

N1 - cited By 0

PY - 2020

Y1 - 2020

U2 - 10.2174/1871527319666200309115602

DO - 10.2174/1871527319666200309115602

M3 - Articolo

VL - 19

SP - 142

EP - 147

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 2

ER -